arrow
A

Andrew Redfern

Harry Perkins Institute of Medical Research
H指数:31
被引数:5,534

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Exploring the feasibility of exercise training during (neo)adjuvant chemotherapy in women with early-stage breast cancer: a pilot study examining immune and metabolic outcomes

探索早期乳腺癌女性在(新)辅助化疗期间进行运动训练的可行性:一项评估免疫和代谢结局的试点研究

2026-09-240
OAAI
Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia

曲妥珠单抗德鲁克替康用于HER2低表达转移性乳腺癌:澳大利亚医学肿瘤学家和病理学家的实用考量

2026-01-010
OAAI
Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First-in-Human Studies in Healthy Participants and Patients

奥西韦尔托(Osivelotor)治疗镰状细胞病的安全性、药代动力学和药效学研究:健康受试者和患者中的首次人体研究

2025-09-020
OAAI
Inhibition of the Caveolin-1 pathway promotes apoptosis and overcomes pan-tyrosine kinase inhibitor resistance in hepatocellular carcinoma

抑制 Caveolin-1 通路促进凋亡并克服泛酪氨酸激酶抑制剂耐药性在肝细胞癌中

2025-07-250
OAAI
Synthetic Epigenetic Reprogramming of Mesenchymal to Epithelial States Using the CRISPR/dCas9 Platform in Triple Negative Breast Cancer

在三阴性乳腺癌中使用CRISPR/dCas9平台的间充质上皮状态的合成表观遗传重编程

2023-05-228
OAAI
CCTG MA40: DOUBLE-BLIND PLACEBO CONTROLLED PHASE III TRIAL OF FULVESTRANT AND IPATASERTIB FOR ADVANCED HER-2 NEGATIVE AND ESTROGEN RECEPTOR POSITIVE (ER plus ) BREAST CANCER POST FIRST LINE CDK 4/6 AND AROMATASE INHIBITOR THERAPY (FINER)
2023-03-010
PRE